Copyright
©The Author(s) 2024.
World J Clin Cases. Dec 6, 2024; 12(34): 6721-6727
Published online Dec 6, 2024. doi: 10.12998/wjcc.v12.i34.6721
Published online Dec 6, 2024. doi: 10.12998/wjcc.v12.i34.6721
Figure 2 Changes in carcinoembryonic antigen and carbohydrate antigen 19-9 tumor marker levels and timeline of the gemcitabine and cisplatin plus durvalumab regimen.
Numbers 1–8 indicate the treatment cycle. “D” indicates durvalumab maintenance therapy. CA 19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen.
- Citation: Igata Y, Kudo M, Kojima M, Kami S, Aoki K, Satake T, Kobayashi T, Sugimoto M, Kobayashi S, Konishi M, Gotohda N. Conversion surgery after gemcitabine and cisplatin plus durvalumab for advanced intrahepatic cholangiocarcinoma: A case report. World J Clin Cases 2024; 12(34): 6721-6727
- URL: https://www.wjgnet.com/2307-8960/full/v12/i34/6721.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i34.6721